BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2016.
World J Gastroenterol. Apr 7, 2016; 22(13): 3632-3643
Published online Apr 7, 2016. doi: 10.3748/wjg.v22.i13.3632
Table 4 Adverse events related to sorafenib administration n (%)
Adverse eventMono-therapy of sorafenib
TACE combined with sorafenib
All eventsGrade 1-2 eventsGrade 3-4 eventsAll eventsGrade 1-2 eventsGrade 3-4 events
Overall incidence14 (93.3)12 (80.0)2 (13.3)30 (90.9)26 (78.8)4 (12.1)
Alopecia6 (40.0)6 (40.0)0 (0.0)11 (33.3)11 (33.3)0 (0.0)
Anorexia4 (26.7)4 (26.7)0 (0.0)18 (54.5)18 (54.5)0 (0.0)
Diarrhea13 (86.7)12 (80.0)1 (6.7)27 (81.8)26 (78.8)1 (3.0)
Epistaxis1 (6.7)1 (6.7)0 (0.0)2 (6.0)2 (6.0)0 (0.0)
Fatigue12 (80.0)12 (80.0)0 (0.0)22 (66.7)21 (63.6)1 (3.0)
Gastrointestinal hemorrhage1 (6.7)1 (6.7)0 (0.0)1 (3.0)1 (3.0)0 (0.0)
Hand-foot skin reactions11 (73.3)10 (66.7)0 (0.0)12 (36.3)11 (33.3)1 (3.0)
Liver dysfunction4 (26.7)4 (26.7)1 (6.7)25 (75.8)23 (69.7)2 (6.0)
Nausea12 (80.0)12 (80.0)0 (0.0)19 (57.6)19 (57.6)0 (0.0)


Write to the Help Desk